NASDAQ: PLURPluri Inc Stock
$2.02-0.23 (-10.22%)
Updated Jun 18, 2026
PLUR Price
$2.02
Fair Value Price
N/A
Market Cap
$21.79M
52 Week Low
$2.00
52 Week High
$5.96
P/E
-0.69x
P/B
-0.9x
P/S
31.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.08M
Earnings
-$25.54M
Gross Margin
43%
Operating Margin
-2,264.32%
Profit Margin
-2,366.9%
Debt to Equity
-1.85
Operating Cash Flow
-$20M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PLUR Overview
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PLUR's potential to beat the market
- PLUR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PLUR
RankedUnranked of 465
RankedUnranked of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important PLUR news, forecast changes, insider trades & much more!
PLUR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PLUR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PLUR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PLUR is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
PLUR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more PLUR due diligence checks available for Premium users.
Valuation
PLUR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.69x
Industry
15.77x
Market
9.47x
PLUR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.9x
Industry
4.95x
PLUR's financial health
Profit margin
Revenue
$167.0k
Net Income
-$5.5M
Profit Margin
-3,322.2%
PLUR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PLUR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$26.1M
Liabilities
$44.7M
Debt to equity
-1.85
PLUR's short-term liabilities ($32.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PLUR's long-term liabilities ($12.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PLUR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PLUR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.5M
Investing
$1.8M
Financing
$1.4M
PLUR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PLUR vs Biotech Stocks
Pluri Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.